-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple sclerosis (MS) is a chronic central nervous system (CNS) inflammatory disease characterized by inflammation, local demyelination, and neurodegenerativeity.
most commonly affected by the disease are whiteness around the brain chamber, optic nerve, spinal cord, brain thymus and the brain.
in the early stages of the disease, inflammatory cells target myelin, which acts as an isolating and supporting axon.
the current treatment of immunoattacks to regulate the disease inhibits inflammatory demyelination lesions (assessed by magnetic resonance imaging) and their accompanying recurrences, but ultimately fails to prevent neurodegenerative changes.
neurodegeneration of MS mainly includes synapses, diffuse synaptic dysfunction and loss of whole neurons, which are related to the patient's long-term disability.
, neurodegenerative changes are reported to be associated with inflammation and demyelination, but the exact cause is still unclear.
this unknown has led to the current lack of treatment for the neurodegenerative phase of MS.
further understanding of THE's neurodegenerative changes and their damage mechanisms may help to develop treatments.
study found an obvious neurodegenerative variant in the secondary multiple sclerosis motor cort, namely the selectivity loss of intermediate neuron subtypes and their connections.
in a preclinical mouse model, we found that this selective vulnerability was secondary to cortical demyelination and affected PV-plus (fast spike intermediate neurons).
loss of intermediate neurons in PV-plus quickly translates into functional neurophysiological damage in inhibitory circuits, providing a link between gray mass demyelination and selective neurodegeneration of inhibitory neuron components.
above, this selective neurodegenerative change observed in rodent models and human MS may be secondary to cortial demyelination, mainly through the loss of intermediate neurons, axons, and synapses.
The new understanding of multiple sclerosis cortological neurodegenerative variants allows us to think more challengingly about neuropythro protection therapies, possibly by providing more targeted support to PV-plus intermediate neurons and selectively increasing their myelin regeneration.
Zoupi, L., Booker, S.A., Eigel, D. et al. Selective vulnerability of inhibitory networks in multiple sclerosis. Acta Neuropathol (2021). MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here